Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition (Q46063040)

19 December 2017

title

Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition (English)

1 reference

19 December 2017

0 references

1 reference

2

1 reference

19 December 2017

author name string

Si Ho Choi

1

1 reference

19 December 2017

Jennifer M Kwan

3

1 reference

19 December 2017

Jean-Pierre J Issa

4

1 reference

19 December 2017

Allen S Yang

5

1 reference

19 December 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

19 December 2017

British Journal of Haematology

published in

1 reference

19 December 2017

volume

138

1 reference

19 December 2017

issue

5

1 reference

19 December 2017

page(s)

616-623

1 reference

19 December 2017

5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06707.X

Increase in Ara-C sensitivity in Ara-C sensitive and -resistant leukemia by stimulation of the salvage and inhibition of the de novo pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06707.X

5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06707.X

DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06707.X

Pharmacokinetics and pharmacodynamics of hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06707.X

The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06707.X

Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06707.X

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06707.X

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06707.X

Cellular differentiation, cytidine analogs and DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06707.X

Sickle cell anemia and antisickling agents then and now.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06707.X

Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06707.X

Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06707.X

Epigenetic therapy of cancer: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06707.X

10.1111/J.1365-2141.2007.06707.X

21 January 2018

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017